Biotechnology

NEW YORK – only the second time, the u.s. Government has adopted the test of human embryonic stem cell treatment in humans — currently rare disease that causes severe Vision will be lost. Advanced cell technology, biotechnology company based in Santa Monica, Calif., said the study should begin at the beginning of next year, following the green light of the u.s. food and drug administration. Only the last month of the second biotechnology company Geron Corp., said that it had begun in the preliminary trials in people with spinal cord injuries substances by injecting cells derived from human embryonic stem cells. Researchers hope to stem cell allows you to create a wide variety of elinpankkien tissues. But human embryos must be destroyed to harvest the cells that you want to change, which has given their use in dispute. ACT: Stargardt disease experiment focuses on the n, which affects only about 30 000 Americans. But the company hopes that the same approach works similar and more common...

Amanda Gardner, HealthDay Reporter Amanda Gardner Reporter Wed Nov – 24 11: 47 pm ET healthday WEDNESDAY, November 24, HealthDay News)--made significant advances in treating Clinical blood cancers at an early stage with the bone marrow and blood stem cells of human origin in recent years, treatment-related complications and death risk to reduce considerably the present level of a new study shows. the 1990s, and 2007 was 41% reduction in between, in the event of death in the analysis of more than 2 500 patients in the Fred Hutchinson Cancer Center in Seattle, blood cancers-the market leader in the field and other malignancies are dealt with in General may present a risk to public health. Fred Hutchinson Cancer Center, researchers who carry out research, stated that the treatment of complications such as infection and dramatic decreases in body injury. A study was published in the New England Journal of Medicine Nov 24 problem "We've made a huge increase in a position to unders...

Maggie Fox, health and Science Editor Maggie Fox, health and Science Editor – Mon Nov 22 6 : 19 pm ET, WASHINGTON (Reuters)-Portland, Oregon, Christopher Goodrich can be expected to stick a needle in her eye. Goodrich hopes one clinical research, which received only in the food and drug administration, only the second research accepted throughout the world to test the human embryonic stem cells in humans, the go-ahead of the first patients enrolled in. Advanced cell technology, a small Massachusetts-based biotechnology company, which has struggled to raise the human embryonic stem cell Lab clinic begins recruitment and Massachusetts patients 12 Oregon rare eye condition, i.e. Stargardt's macular dystrophy. Goodrich, 55, retired last year in his job as a coordinator of Portland State University services veteran's macular dystrophy when his Stargardt viewing experience, and suddenly deteriorated. Like most patients Goodrich had seen his Vision to get steadily worse his young adul...